Gastroprotective Efficacy of Rebamipide in Patients With Atrial Fibrillation Treated With DOACs

Inclusion Criteria: * Men and women from 18 till 80 years old * Patients with atrial fibrillation (AF) and a moderate or high risk of thromboembolic complications (\>=1 point in men and \>=2 points in women according to the CHA2DS2VASc scale), receiving DOAC (rivaroxaban, apixaban or dabigatran) for the prevention of thromboembolic complications * The following indications for the use of rebamipide and/or pantoprazole: * Chronic gastritis with high acidity in combination with gastroesophageal reflux disease * Peptic ulcer if negative test for H. pylori * Сhronic erosive gastritis * Need for Exclusion Criteria: * Refusal to participate in the study * Participation in any other clinical trial or taking study drugs within 3 months before enrollment; * Contraindications to study procedures * Participation in the study is unsafe according to the investigator opinion. * Admission of prohibited medication * Pregnancy and lactation, as well as the inability to use reliable contraception in women of childbearing age * Peptic ulcer in the acute stage * Acute erosion on screening visit